Active Stocks in Review: American Capital Ltd. (NASDAQ:ACAS), TeamHealth Holdings Inc (NYSE:TMH), SAGE Therapeutics Inc (NASDAQ:SAGE)

American Capital Ltd. (NASDAQ:ACAS) fall -0.24% during last trading as the stock less -$0.04 to finish the day at $16.54 with about 914,011.00 shares changing hands, compared to its three month average trading volume of 933,315.00. The $3.55B market cap company, which fluctuated between $16.52 and $16.57 during the day, currently situated 38.76% above its 52 week low of $11.92 and -0.48% away from its one year high of $16.62. The RSI of 60.03 indicates the stock is overbought at the current levels, sell for now. American Capital, Ltd. (American Capital) is a global asset manager and private equity firm. American Capital, both directly and through its asset management business, originates, underwrites and manages investments in middle market private equity, leveraged finance, real estate, energy and structured products.

TeamHealth Holdings Inc (NYSE:TMH) fall -$0.07 to close the day at a new closing price of $34.74, a -0.07% decrease in value from its previous closing price that moved the stock 4.80% above its 52 week low of $33.15. A total of 913,556.00 shares exchanged hands during the day compared with its three month average trading volume of 559,688.00. The stock, which fluctuated between $34.13 and $35.09 during the day, currently situated -45.71% below its 52 week high. The stock is down by -19.08% in the past one month and down by -23.31% over the past three months. With a one year target estimate of $48.53 and RSI of 26.55, the stock still has upside potential, making it a hold for now. Team Health Holdings, Inc. (TeamHealth) is a provider of outsourced healthcare professional staffing and administrative services to hospitals and other healthcare providers. The Company operates through four segments: Hospital Based Services, IPC Healthcare, Specialty Services and Other Services.

SAGE Therapeutics Inc (NASDAQ:SAGE) had a light trading with around 910,709.00 shares changing hands compared to its three month average trading volume of 1.21M. The stock traded between $35.74 and $36.69 before closing at the price of $36.45 with 0.19% change on the day. The company is currently trading 38.70% above its 52 week low of $26.28 and -41.81% below its 52 week high of $62.64. Both the RSI indicator and target price of 42.98 and $77.00 respectively, lead us to believe that it could drop over the coming weeks. SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. Its lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor.